Our Founders
Our Founders
Our Founders
 |
|---|
Developing an Immunostimulatory Agent to Treat Cancer
About Mosaic
Our mission is to develop a first-in-class plant virus nanoparticle to help patients with cancer fight their disease
Our Technology
Our lead immunoncology candidate, MIE-101, is based on a plant virus that is not infectious, but is recognized as danger signal by the immune system. Direct injection of the plant virus nanoparticle into a tumor results in a robust local immune response inside the tumor that recruits immune cells that respond to and are activated by the plant virus and ultimately target the tumor itself. Anti-tumor immune responses within the treated tumor initiate
immune surveillance resulting in systemic antitumor immunity and destruction of distant metastatic disease. The science supporting MIE-101 was the result of over twenty million dollars in research funding and has been widely published in leading peer-reviewed scientific journals.
Immuno-Oncology - Humans
MIE-101 is based on the plant virus cowpea mosaic virus (CPMV) which is infectious to certain plants but not to animals including mice, dogs and humans. CPMV does however resemble features of mammalian viruses, including its outer protein structure and its genetic nucleic acid, both components of which are recognized by the innate immune system through pattern recognition receptors (PRRs) . The plant viral nanoparticle is directly administered into the tumor to activate the immune system within and elicit local and system anti-tumor immunity.
Immuno-Oncology - Companion Animals
Mosaic IE's lead veterinary compound MIE-201, is based on exactly the same concept as its lead human oncology product candidate and has demonstrated promising antitumor effects as a monotherapy and in combination with standard of care such as chemotherapy and radiation in dogs with spontaneous solid tumors.
New studies are planned to help inform development of the platform in human cancer patients while also exploring the potential in companion animals.
Vaccines
The emergence of COVID-19, caused by SARS-CoV-2, highlights the need for a vaccine platform that enables rapid antigen discovery and vaccine development. Nanotechnology provides an innovative approach to vaccine development by producing nanoparticles capable of mimicking viral structures and supporting next-generation vaccine design
